CClinicalTrials.gg
Sign In
Status unknownNCT04708340RJXUpdated Mar 15, 2022

Tolerability and Efficacy of RJX in Patients With COVID-19

A Phase 1/2 interventional study of Rejuveinix (RJX) Active Comparator and Placebo Comparator in COVID-19, Acute Respiratory Distress Syndrome and SARS-CoV-2, sponsored by Reven Pharmaceuticals, Inc.. Status unknown at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Reven Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled, multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in patients with COVID-19.

Read the detailed description

For each cohort, there will be an open label Safety Lead-in (Part 1) and a placebo controlled, randomized, double-blind portion (Part 2). In Part 1, RJX will be administered daily for 7 days. In the active treatment arm of Part 2 for both cohorts, RJX will be administered daily for 7 days per cycle and patients may receive up to 2 cycles. As detailed below, patients will be allowed to receive a second 7 day cycle of therapy based on the medical judgment of the Investigator. The total RJX exposure during Part 2 could therefore be up to 14 days. Both cohorts will start and enroll in parallel and independently. A safety follow-up period will begin at Day 14/Discharge, or when treatment is discontinued, and will continue for approximately 60 days post discharge. Part 1 will be conducted at a single site and Part 2 will be conducted at multiple sites. The 2 cohorts in this study are:

  • Cohort 1:

    • Hospitalized COVID-19 patients ≥18 years without hypoxemia who are either not receiving any oxygen therapy OR are receiving supplemental oxygen via mask or nasal prongs (namely, clinical status score 4 or 5 on an 8-point ordinal scale).

    • Patients are required to have the following high-risk characteristics

      1. Age ≥65 years AND type 2 diabetes or hypertension OR

      2. Age ≥18 years with abnormal blood tests AND CRP >50 mg/L PLUS at least 1 of the following biomarkers:

        1. D-dimer >1,000 ng/mL,
        2. Ferritin >500 µg/L,
        3. High sensitivity cardiac troponin >2 × upper limit of normal (ULN),
        4. LDH >245 U/L.

  • Cohort 2:

    • Hospitalized COVID-19 patients with hypoxemia without ARDS who are receiving either non-invasive positive pressure ventilation (NIPPV) OR high flow oxygen (namely, clinical status score 3 on an 8-point ordinal scale).
02

Conditions studied

  • COVID-19
  • Acute Respiratory Distress Syndrome
  • SARS-CoV-2
  • Hypoxemia
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 237 is above the median of 100 across 4,098 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Reven Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Cohort 1 (Part 1 and Part 2):

  1. Hospitalized COVID-19 patients ≥18 years without hypoxemia who are either not receiving any oxygen therapy OR are receiving supplemental oxygen via mask or nasal prongs (namely, clinical status score 4 or 5 on an 8-point ordinal scale)
  2. Hospitalized COVID-19 patients age ≥65 years AND type 2 diabetes or hypertension, OR

  3. Hospitalized COVID-19 patients ≥18 years AND abnormal blood tests with CRP >50 mg/L PLUS at least 1 of the following biomarkers:

    1. D-dimer >1,000 ng/mL
    2. Ferritin >500 µg/L
    3. High sensitivity cardiac troponin >2 × ULN
    4. LDH >245 U/L

    Cohort 2 (Part 1 and Part 2):

  4. Hospitalized COVID-19 patients with hypoxemia who are either receiving NIPPV OR high-flow oxygen (namely, clinical status score 3 on an 8-point ordinal scale).
  5. Bilateral opacities on a chest x-ray OR chest CT scan. Cohort 1 and Cohort 2 (Parts 1 and 2)
  6. Male and non-pregnant, non-lactating female patients with SARS-CoV-2 infection that is documented by a Food and Drug Administration (FDA)-authorized diagnostic reverse transcription polymerase chain reaction test at/or within 4 days of Screening
  7. ≥18 years of age
  8. Body weight ≥40 kg at Screening
  9. History of COVID-19 within the last 2 weeks prior to study enrollment
  10. The patient OR a legally authorized representative has provided written informed consent
  11. Females of childbearing potential must have a negative beta human chorionic gonadotropin pregnancy test at Screening
  12. Females of childbearing potential must agree to be abstinent or else use a medically acceptable form of contraception from the Screening period through Day 28. Medically acceptable forms of contraception including implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomy, and double-barrier method [condom and occlusive cap (diaphragm or cervical/vault caps)] with spermicidal foam/gel/film/suppository

Exclusion criteria

Exclusion Criteria Cohort 1

  1. Receiving high-flow oxygen OR NIPPV. Cohort 1 and Cohort 2
  2. ARDS by Berlin definition (Appendix 16.2)
  3. On extracorporeal membrane oxygenation
  4. Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg and/or diastolic BP >100 mmHg), unstable angina, congestive heart failure of New York Heart Association Classification Class III or IV (i.e., Class III: marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances [20 100 m], comfortable only at rest; Class IV: severe limitations, experiences symptoms even while at rest, mostly bedbound patients), serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 12 months prior to enrollment
  5. Subjects with a history of congenital long QT syndrome or of Torsades de pointes; subjects with bradycardia (\<60 bpm), heart block (excluding 1st degree block, being PR interval prolongation only); subjects with any of the following findings on electrocardiogram (ECG): QTc interval >470 msec in women OR >450 msec in men; subjects requiring any drugs known to prolong the QTc interval, including antiarrhythmic medications
  6. Shock or hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine
  7. Renal function impairment with creatinine ≥2 mg/dL
  8. Liver function impairment with total bilirubin ≥2 mg/dL
  9. Platelet count \<50,000/µL
  10. Multi-organ failure
  11. History of an allergic reaction or hypersensitivity to the study drug or any component of the study drug formulation
  12. Use of systemic corticosteroids, nonsteroidal anti-inflammatory drugs, antibiotics, and antiviral drugs that are not part of the standard of care
  13. Presence of any uncontrolled concomitant illness (e.g., bacterial sepsis or invasive fungal infection), or other serious illness and medical conditions, or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with their participation in the study
  14. Pregnancy or breast-feeding (for women)
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
237 participants (estimated)

Study arms

  • Active comparator
    Arm A: RJX

    1. RJX 20 mL (10 mL of Vial A plus 10 mL of Vial B) mixed in normal saline, total volume 120 mL, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily. 2. Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment). 3. Patients in Part 1 are allowed to receive only one 7-day cycle of RJX while patients in Part 2 may be treated daily for up to 14 days.

    Drug: Rejuveinix (RJX) Active Comparator

  • Placebo comparator
    Arm B: Placebo

    1. Placebo (total of 20 mL normal saline) mixed in normal saline IV, total volume 120 mL of normal saline IV, administered by IV infusion over a period of 40 minutes +/- 10 minutes once daily. 2. Standard of care (current antiviral and/or supportive care treatment currently in place at the institution for COVID-19 treatment). 3. Patients in Part 1 will not receive placebo. 4. Patients in Part 2 may be treated daily for up to 14 days.

    Drug: Placebo Comparator

Interventions

  • DrugRejuveinix (RJX) Active Comparator

    Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.

    Also known as: RJX, Rejuveinix

  • DrugPlacebo Comparator

    0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection

    Also known as: 0.9% Sodium Chloride in Water for Injection, USP., Normal Saline for Injection, USP

06

What researchers measure

Primary outcomes

  1. Safety as measured by DLTs and drug related SAE's

    • Part 1, Cohorts 1 and 2: Cumulative incidence of DLTs and drug-related SAEs (viz., sum of DLT + SAEs) reported within 14 days of first dose of RJX (Part 1) or reported within 60 days of first dose of study drug (Part 2)

    Time frame: Up to 60 days post-enrollment

  2. Tolerability and Efficacy measured by progression of disease through an ordinal scale.

    • Part 2, Cohort 1: Progression to severe disease on an 8-point ordinal scale from a clinical status score of 4 or 5 to a clinical status score of 3, 2, or 1 within 2 weeks of first dose of study drug

    Time frame: Within 2 weeks

  3. Efficacy measured by time to resolution of respiratory failure

    • Part 2, Cohort 2: Time to resolution of respiratory failure (TTRRF), with status change on an 8-point ordinal scale from a clinical status score of 3 to a clinical status score of ≥4

    Time frame: 60-days post enrollment

Secondary outcomes

  1. Efficacy as measured by day of ICU care.

    The key secondary endpoints for Parts 1 and 2, Cohorts 1 and 2 are: • Mean number of days of ICU care

    Time frame: 60-days post enrollment

  2. Safety, Tolerability, Efficacy measured by mortality over 28 Days.

    The key secondary endpoints for Parts 1 and 2, Cohorts 1 and 2 are: • Proportion of patients that die (any cause) by Day 28 post randomization (patient may be inpatient or outpatient in follow up)

    Time frame: 28-days post enrollment

  3. Efficacy measured by mean change in baseline clinical status on Days 7 and 14.

    Additional secondary endpoint for Parts 1 and 2, Cohorts 1 and 2 are: • Mean change from baseline of clinical status using an 8-point ordinal scale (with 8 being "Not hospitalized, no limitations on activities", and 1 being "Death") at Days 7 and 14

    Time frame: 14-days post enrollment

  4. Efficacy measured by mean change in hospitalization days on Days 7 and 14.

    Additional secondary endpoint for Parts 1 and 2, Cohorts 1 and 2 are: • Mean number of hospitalization days

    Time frame: 14-days post enrollment

  5. Efficacy measured by time to coming off supplemental oxygen on Days 7 and 14.

    Additional secondary endpoint for Parts 1 and 2, Cohorts 1 and 2 are: • Time to coming off supplemental oxygen (defined as a score of ≥5 on an 8-point ordinal scale; Cohort 1 only)

    Time frame: 14-days post enrollment

  6. Safety and Efficacy measured by time from first dose to renal therapy.

    Additional secondary endpoint for Cohort 2, Part 2 is: • Time to initiation of renal replacement therapy

    Time frame: 60-days post enrollment

Other outcomes

  1. Evaluate Change in Serum CRP Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of CRP (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  2. Evaluate Change in Serum Ferritin Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of ferritin (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  3. Evaluate Change in Serum D-dimer Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of D-dimer (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  4. Evaluate Change in Serum LDH Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of LDH (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  5. Evaluate Change in Serum IL-6 Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of IL-6 (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  6. Evaluate Change in Serum IL-10 Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of IL-10 (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  7. Evaluate Change in Serum TNF-α Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of TNF-α (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  8. Evaluate Change in Serum TGF-β Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of TGF-β (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  9. Evaluate Change in Serum C3 Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of C3 (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  10. Evaluate Change in Serum C5 Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of C5 (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  11. Evaluate Change in Plasma ascorbic acid Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of ascorbic acid (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  12. Evaluate Change in plasma niacinamide Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of niacinamide (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  13. Evaluate Change in plasma thiamine Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of thiamine (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

  14. Evaluate Change in plasma cyanocobalamin Concentration

    The exploratory endpoint for Parts 1 and 2 is: Kinetic of response of cyanocobalamin (comparison of baseline to Day 7, Day 14, and Day 28 post-randomization). These laboratory measures will be obtained either as an inpatient or an outpatient follow-up.

    Time frame: Up to 28-days post randomization

07

Study locations

3 sites
  • Memorial Hermann Memorial City Medical Center
    Houston, Texas 77024, United States
  • Memorial Hermann Southeast Hospital
    Houston, Texas 77089, United States
  • Christus Santa Rosa Hospital
    New Braunfels, Texas 78130, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04708340
Lead sponsor
Reven Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2021
Start date
Mar 25, 2021
Primary completion
Oct 2022 (estimated)
Completion
Feb 2023 (estimated)
Last update
Mar 15, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

Reven Pharmaceuticals, Inc.

Start the discussion